This will play a video - couple on bicycles

TREAT MORE PATIENTS EVOLUTTM TAVI PLATFORM FOR SSAS LOW RISK PATIENTS

A 2 YEAR FOLLOW UP

The 2 years1 complete follow up has demonstrated:

  • TAVI noninferiority to surgery: primary endpoint 4.3% for TAVI vs 6.3% for SAVR. 
  • Valve thrombosis rates remained low at two years. 
  • Hemodynamics were significantly better for TAVI at all time points.
DISCOVER THE 2 YEARS FOLLOW UP
Animation of Evolut Pro TAVR showing the three leaflets opening and closing into the aorta

Superior HEMODYNAMICS

Evolut™ TAVI is the only TAVI device to demonstrate hemodynamic superiority in a low risk clinical trial vs. SAVR at two years.*

Learn about HEMODYNAMICS

Indications, Safety, and Warnings

SUPERIOR
EFFECTIVE ORIFICE AREAS (EOA)

EvolutTM TAVI
2.2 cm2 
vs.
SAVR 2.0 cm2

arrow up

SUPERIOR Gradients
 
 

EvolutTM TAVI
9.0 mm Hg
vs.
SAVR 11.7 mm Hg

arrow pointing down

SAFE and EFFECTIVE

As demonstrated by all-cause mortality or disabling stroke, noninferior to SAVR at 24 months1

tavi numbers

EvolutTM TAVI compared to SAVR

EvolutTM TAVI showed lower mortality, fewer disabling strokes, and fewer heart failure rehospitalisations compared to SAVR2

graph
Low risk graph displayed

Less Patient Prosthesis Mismatch.

Better Patient Outcomes.<sup>3,*</sup>

LEARN MORE ABOUT PPM

PATIENT PROSTHESIs
MIsMATCH MATTERS

Calculate your patient's risk of prosthesis mismatch.

PPM Calculator

EVOLUTTM TAVI BICUSPID INDICATION

LEARN MORE
tavi low risk animation

Contact Us to Learn More

*Indicates Required Field

Your information will be processed and protected in accordance with our privacy statement

Selecting “no” to marketing emails above will not affect your other email selections, and a Medtronic representative will still reach out via email, if selected. Your personal data will used to manage your relationship with Medtronic, and, if you consent, to provide you with relevant email updates based on your user preferences. You can opt-out of receiving such emails at any time by clicking the unsubscribe link in the relevant email. Medtronic may use pixels and other technologies in emails to gather statistics around email opening and clicks, to help us improve our communications and to provide you with relevant content. For more information, see the Medtronic privacy notice.

You can always change your preferences or update your personal details by visiting the Preference center.

See the Preference center

1. Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. May 2, 2019;380(18):1706-1715.

2. Reardon MJ. The Evolut Low Risk Trial. Presented at ACC 2019; New Orleans, LA.

3. Herrmann HC, Daneshvar SA, Fonarow GC, et al. Prosthesis-Patient Mismatch in 62,125 Patients Following Transcatheter Aortic Valve Replacement: From the STS/ACC TVT Registry. J Am Coll Cardiol. Published online September 18, 2018.

*Forrest J.K. M.D. On behalf of the Evolut Low Risk Investigators. The Evolut Low Risk Trial Complete 2-year follow-up. Presented at EuroPCR 2021.

SSAS = Symptomatic Severe Aortic Stenosis